A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

NCT06671379 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SHR-A2009 monotherapy
DRUG: platinum-based dual-agent chemotherapy

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.